PharmAbcine的PMC-403抗体获得NAMD第1阶段一致的安全批准,进入多个升剂量阶段。 PharmAbcine's PMC-403 antibody receives unanimous Phase 1 safety approval for nAMD, proceeding to multiple ascending dose phase.
韩国生物技术公司PharmAbcine在针对新血管与年龄相关的黄斑退化 (nAMD) 的第一阶段临床试验中获得了其PMC-403抗体的一致安全批准. PharmAbcine, a South Korean biotech firm, has received unanimous safety approval for its PMC-403 antibody in a Phase 1 clinical trial targeting neovascular age-related macular degeneration (nAMD). 该试验针对的病人对标准的抗VEGF疗法没有反应,现在将进入多重上升剂量阶段。 The trial, aimed at patients unresponsive to standard anti-VEGF therapies, will now proceed to a multiple ascending dose phase. PMC-403稳定了漏泄的血管,对眼科以外的各种情况很有希望,计划在安全确认后进行第二阶段试验。 PMC-403, which stabilizes leaky blood vessels, shows promise for various conditions beyond ophthalmology, with plans for a Phase 2 trial following safety confirmations.